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Febrile neutropenia (FN) represents one of the most common complications 
of chemotherapy in cancer patients1. Chemotherapy induced neutropenia remains a 
life threatening complication despite progress in our understanding and in the 
treatment of this event. Now days the accepted standard of care for such patients 
has been administration of empiric, broad spectrum antibiotics, and close monitoring 
for development of complications until fever resolution and neutropenia recovery. 
Though treatment of such patients can be done as in-patients in hospitals, not all 
febrile neutropenia patients require intensive treatment2.  
 
Many investigations have indicated that neutropenic patients with fever are a 
heterogeneous population, with subsets with varying risks regarding response to 
initial therapy, development of serious medical complications, and mortality. Over the 
past decade, several investigators have identified subsets of febrile neutropenic 
patients who are at low risk for the development of complications, including mortality. 
Several clinical studies involving neutropenic patients with predicted low risk have 
demonstrated the feasibility of newer approaches, such as outpatient therapy after 
early discharge from the hospital or outpatient therapy for the entire febrile episode, 
using parenteral, sequential (intravenous [IV] followed by oral), or oral antibiotic 
regimens3. 
 
Febrile Neutropenia can be defined   as a single oral temperature ≥ 38.3°C or 
101°F or a temperature of ≥ 38°C or 100.4°F for at least 1 hour 5. , With absolute 
neutrophil count (ANC) < 500 cells/mm3 or an ANC < 1,000 cells/mm3 with a 
predicted decline to < 500 cells/mm3. 
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At least one-half of febrile neutropenic patients have a documented or occult 
infection. At least one-fifth of patients with neutrophil counts < 100 cells/mm3 have 
bacteremia. Fungi can be causes of secondary infection in neutropenic patients who 
have received broad-spectrum antibiotics and may also cause primary infections. 
The primary anatomic site of infection is the gastrointestinal tract, where mucosal 
damage from chemotherapy allows invasion of micro-organisms. Damage to the skin 
from invasive procedures, such as intravascular devices, similarly provides portals of 
entry for microbes.  
 
The duration of neutropenia is also an important determinant of risk of 
infection. Patients with a low ANC and prolonged neutropenia (eg, > 10 days) are at 
further increased risk of infection 7. 
 
Risk assessment is important in deciding whether febrile neutopenic patients 
can be treated as inpatients or outpatients and whether oral or intravenous 
antibiotics can be used. Historically, characteristics of low risk for serious medical 
complications include outpatient conventional chemotherapy for solid tumors, normal 
chest x-ray, hemodynamic stability, expected duration of neutropenia ≤ 7 days, 
normal kidney and liver function tests, early evidence of marrow recovery, 
malignancy in remission, and normal mental status. 
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Management of patients with febrile neutropenic fever is complex and 
involves careful consideration of multiple factors. At least one-half of neutropenic 
patients who become febrile have a documented or occult infection. The 
microbiology of infections has shifted, with more gram-positive infections, increased 
drug resistance, and previously less common organisms being seen more frequently. 
Risk assessment is needed to determine whether inpatient or outpatient treatment is 
indicated and whether intravenous or oral antibiotics can be used 7. 
 
A thorough history is extremely important when evaluating patients for febrile 
neutropenia. The history should include the nature of the chemotherapy given, prior 
antibiotic prophylaxis, concomitant steroids or other immunosuppressive’s, recent 
documented colonization or infection with susceptibilities, recent surgical 
procedures, and medication allergies.  
 
In neutropenic patients, symptoms and signs of inflammation may be minimal 
or absent. The lack of inflammatory response can make detection of infection more 
difficult and requires close physical examination for more subtle signs and 
symptoms. There will likely be decreased erythema, induration, and purulence in 
response to bacterial infections (eg, a skin infection without typical features of 
cellulitis, a pulmonary infection without a clear infiltrate, meningitis that lacks 
cerebrospinal fluid pleocytosis, and urinary tract infections without pyuria). Careful 
evaluation of common sites of infections should include the mouth, pharynx, 
esophagus, lungs, perineum, eyes, skin, and vascular catheter access sites.  
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Laboratory studies include measurement of complete blood counts, serum 
creatinine levels, blood urea nitrogen, transaminase levels, and blood cultures. Blood 
cultures should be obtained from a peripheral vein and catheter if present. 
Depending on the clinical situation, other cultures can be obtained. Skin biopsies can 
also be obtained if indicated. If respiratory signs or symptoms are present, a chest x-
ray can be performed6. 
 
There is a growing interest in designing risk-adapted strategies for the 
management of FN. The administration of parenteral, broad-spectrum empirical 
antibiotic therapy after the hospitalisation of patients with FN is the accepted 
standard of care. 
 
This approach is effective (with an infection-related mortality rate of less than 
10%) but is expensive and, when applied to all patients with FN, may represent a 
suboptimal use of resources. Over the past decade, the development of risk 
stratification models has allowed for the identification of low-risk patients with 
additional treatment strategies, such as initial hospitalisation followed by early 
discharge with parenteral or oral antibiotics (sequential therapy) and out-patient 
treatment with oral antimicrobials.  
 
The most attractive option is out-patient treatment for the entire febrile 
episode, because of several advantages, including important repercussions on 
economic costs and quality of life as well as significant reduction in nosocomial 
super infections. Careful selection of patients at a low risk of developing 
complications, appropriate empirical regimens and the daily monitoring of patients 
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(for response and toxicity) are critical for the success of this approach. Expected 
duration of neutropenia (less than 10 days and under 60 years of age) and 
favourable social and economic environment, with access to prompt medical 
attention, are relevant prerequisites for considering this approach 11 . 
 
Epidemiology of infection is influenced not only by the severity and duration of 
neutropenia, but also by the intensity of chemotherapy, the use of prophylaxis and/or 
empirical antibiotic therapy, the use of central venous catheters, environmental 
factors and duration of the hospital stay, among others.  
 
The detection of epidemiological shifts requires frequent monitoring and 
surveillance, particularly at centres treating large numbers of patients, as institutional 
differences can be substantial. For example, in recent years, some hospitals have 
experienced an increase of infections caused by multidrug-resistant gram-negative 
bacilli, such as Acinetobacter species or Stenotrophomonas maltophilia, and gram-
positive cocci with increasing resistance to glycopeptides.Many reports have 
demonstrated the emergence gram-positive organisms in patients with neutropenia. 
 
The practice of antimicrobial prophylaxis has been questioned repeatedly. 
Although oral prophylaxis against bacterial and fungal infections may decrease the 
risk of development of infections after bone marrow transplantation or chemotherapy, 
these practices also promote the emergence of drug-resistant strains (particularly 
fluoroquinolone-resistant Escherichia coli and fluconazole-resistant non-albicans 
Candida species). The use of fluoroquinolones for prophylaxis in high-risk patients 
with neutropenia has been also associated with the emergence of resistance among 
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Pseudomonas aeruginosa isolates (more than 20% at some institutions). The 2002 
guidelines from the Infectious Diseases Society of America (IDSA) did not 
recommend the routine fluoroquinolone prophylaxis during neutropenia. However, 
this may be considered for high-risk patients in critical periods of time 11. 
 
Several predictive models have indeed been developed to identify patients at 
low risk of complications. Two classification systems are notable, Talcott 
classification of risk groups and a scoring system proposed by the Multinational 
Association for Supportive Care in Cancer (MASCC) group. Both systems use 
serious medical complications as the endpoint for risk prediction. However, the 
sensitivity of the Talcott classification is limited (approximately 30%), and the 
misclassification rate is high. For example, many patients who do not have 
complications are not identified by the prediction rule. Also, when the classification 
system was used on patients discharged for home intravenous antibiotics after 2 
days of inpatient observation, the complication rate was higher than anticipated, The 
so-called Multinational Association for Supportive Care in Cancer (MASCC) scoring 
system has been internationally validated under various clinical conditions and has 
been widely accepted. The use of the MASCC score also allows the selection of low-
risk patients who can be safely treated with orally administered antibiotics and be, for 
at least some of them, successfully discharged early after a 24-h in-hospital 
observation1,3. 
 
Febrile neutropenic cancer patients will have different risk of developing a 
serious infection related complications. Although, there are no universally accepted 
criteria to recognise these patients, currently the most used model of prediction of 
12 
 
complications is the multinational association of supportive care (MASCC) index 
score2. 
 
This study was designed to validate MASCC index score in an attempt to 
accurately predict, on presentation with febrile neutropenia, which cancer patients 
are at low or high risk of developing serious medical complications during the 
episode. 
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The primary objective of this study was to validate the performance of the  
Multinational Association for  Supportive Care in Cancer (MASCC) risk index, in 
predicting the outcome of febrile neutropenia in adult cancer patients in the local 
health care setting of Cancer institute ,chennai.  
The secondary objectives included the evaluation of the clinical outcome, 
infective aetiology and prognostic factors of febrile neutropenia in the local 
population. 
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The Multinational Association for Supportive Care in Cancer (MASCC) Risk 
Index can be used to identify low-risk patients (score ≥21 points) for serious 
complications of febrile neutropenia (including death, intensive care unit admission, 
confusion, cardiac complications, respiratory failure, renal failure, hypotension, 
bleeding, and other serious medical complications). The score was developed to 
select patients for therapeutic strategies that could potentially be more convenient or 
cost-effective.  
 
A prospective trial demonstrated that a modified MASCC score can identify 
patients with febrile neutropenia at low risk of complications as well. Here is review 
of literature of some studies who used different scores and tried to identify various 
prognostic markers in febrile neutropenia 
 
M.Bykara et al, study was determine the clinical significance of lymphopenia 
and monocytopenia in terms of its duration and depth in patients with febrile 
neutropenia and MASCC scores parameters. Sixty-six patients with febrile 
neutropenia were prospectively analysed. Recurrent febrile neutropenia episodes 
were excluded in this trial. Twenty-four patients had solid tumours, 42 patients had 
lymphoma-leukaemia. Patients with MASCC-scores  21 evaluated as low-risk and 
the ones with their scores <21 were high-risk. Concluded the depth of 
monocytopenia and durations of lymphopenia and monocytopenia were the 
important parameter influencing antibiotic modification in febrile neutropenia. 
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Jean Klastersky, Marianne Paesmans, Edward B. Rubenstein et al did a study  
to develop an internationally validated scoring system to identify these patients. (756 
patients), predictive factors were a burden of illness indicating absence of symptoms 
or mild symptoms (weight, 5; odds ratio [OR], 8.21; 95% confidence interval [CI], 
4.15 to 16.38) or moderate symptoms (weight, 3; OR, 3.70; 95% CI,2.18 to 6.29); 
absence of hypotension (weight, 5; OR, 7.62; 95% CI, 2.91 to 19.89); absence of 
chronic obstructive pulmonary disease (weight, 4; OR, 5.35; 95%CI, 1.86 to 15.46); 
presence of solid tumor or absence of previous fungal infection in patients with 
hematologic malignancies (weight, 4; OR, 5.07; 95% CI, 1.97 to 12.95); outpatient 
status (weight, 3; OR, 3.51; 95% CI,2.02 to 6.04); absence of dehydration (weight, 3; 
OR,3.81; 95% CI, 1.89 to 7.73); and age less than 60 years (weight, 2; OR, 2.45; 
95% CI, 1.51 to 4.01). On the validation set, a Multinational Association for 
Supportive Care in Cancer risk-index score > 21 identified low-risk patients with a 
positive predictive value of 91%, specificity of 68%, and sensitivity of 71%.The risk 
index accurately identifies patients at low risk for complications and may be used to 
select patients for testing therapeutic strategies that may be more convenient or 
cost-effective3.  
 
Almarie Uys et al, prospectively validated the Multinational Association of 
Supportive Care of Cancer (MASCC) risk-index score in an attempt to accurately 
predict on presentation with febrile neutropenia those cancer patients who are at low 
or high-risk for development of serious medical complications during the episode. Of 
the 80 febrile neutropenic episodes, 58 were classified as low risk and 22 as high-
risk patients. They correctly predicted 98.3% of low-risk patients and 86.3% of high-
risk patients. This study had a positive predictive value of 98.3%and a negative 
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predictive value of 86.4% with both a sensitivity and specificity of 95%, concluded 
that MASCC risk index score correctly identifies low and high-risk patients at 
presentation with febrile neutropenia4 
 
Marianne Paesmans et al did study to investigate the possible interaction 
between the MASCC score and bacteremic status and to assess whether, assuming 
that bacteremic status could be predicted at onset of febrile neutropenia, adding 
bacteremia as a covariate in a risk model would improve the accuracy of low-risk 
patients identification. Two consecutive multicentric observational studies were 
carried out from 1994 till 2005 involving 2,142 febrile neutropenic patients. The study 
data bases were retrospectively used for the present analysis a clinical prediction 
rule integrating the MASCC score and the bacteremic status was not helpful in 
improving the identification of low-risk patients1. 
 
Edwin Pun Hui & Linda K. S. Leung et al validated the Multinational 
Association for Supportive Care in Cancer (MASCC) risk index, and compared it with 
the Talcott model and artificial neural network (ANN) in predicting the outcome of 
febrile neutropenia in a Chinese population. Total 227 patients were enrolled. 
Serious medical complications occurred in 22% of patients and 4% died. The 
positive predictive value of low risk prediction was 86% (95% CI=81–90%) for 
MASCC score≥21, 84% (79–89%) for Talcott model, and 85% (78–93%) for the best 
ANN model. The sensitivity, specificity, negative predictive value, and 
misclassification rate were 81%, 60%, 52%, and 24%, respectively, for MASCC 
score≥21; and 50%, 72%, 33%, and 44%, respectively, for Talcott model; and 84%, 
60%, 58%, and 22%, respectively, for ANN model. In the low risk group identified by 
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MASCC score≥21 (70% of all patients)12.5% developed complications and 1.9% 
died, compared with 43.3%, and 9.0%, respectively, in the high risk 
group(p<0.0001).Concluded that MASCC risk index validated in a Chinese 
population demonstrated a better over all performance than the Talcott model  and 
was equivalent to ANN model5. 
 
G.H. Lyman, J. Crawford et al designed a Risk Model for First-Cycle Febrile 
Neutropenia in Cancer Patients Receiving Systemic Chemotherapy in their study , Of 
296 patients experiencing febrile neutropenia, 171 (58%) did so during cycle 1; use 
of prophylactic growth factors was reported in just 8.7% of patients. In their study 
according to excellent test performance characteristics, the risk model identified 
patients at increased risk for febrile neutropenia occurring during cycle 1 of 
chemotherapy for possible targeted prophylaxis with filgrastim or pegfilgrastim. 
Currently, this model in phase II of this ongoing registry study is being validated. 
Catherine Cordonnier, Raoul Herbrecht et al 8studied the risk of Gram negative 
bacterial infections in febrile neutropenic patients and to develop a specific risk 
score. This prospective study included 513 consecutive febrile neutropenic, 
evaluable patients. Forty-five per cent of the patients were receiving prophylactic gut 
decontamination, and 6% were receiving prophylactic quinolones at the onset of 
febrile neutropenia. Data were collected from the onset of febrile neutropenia until 30 
days later. Risk factors for Gram-negative bacterial infection were identified by 
comparing baseline characteristics of patients with and without Gram-negative 
bacterial infection. Independent risk factors in multivariate analysis were used to 
build a predictive score for Gram-negative bacterial. They concluded that their 
scoring system identifies patients with a high probability of Gram-negative bacterial 
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infection as those with a score 3. If confirmed in a validation set, this score could be 
considered in the choice of the first-line antibiotics in febrile neutropenic patients. 
 
Rebecca B. Donohue and Glen Carbo et al9 did retrospective study to 
Develop a neutropenia risk-assessment tool appropriate for the management of 
neutropenia and its complications in a small oncology practice. Study design was 
that ten relevant studies published in medical and nursing journals were identified 
using the Evidence-Based Utilization Framework to search the literature. Pertinent 
patient variables were extracted from the literature search and included a 
chemotherapy regimen with a ≥ 40% risk of development of febrile neutropenia, 
advanced age (≥ 70 years), and treated with combination chemotherapy, bone-
marrow involvement and/or compromise, open wounds, prior occurrence of febrile 
neutropenia, a serum albumin level ≤ 3.5 g/dL, and a first-cycle absolute neutrophil 
count (ANC) ≤ 500/μL. Patients with one or more risk factors were considered to be 
at high risk for the development of neutropenia and were given growth-factor support 
with a colony-stimulating factor (CSF), as well as education about neutropenia and 
its complications, following a predetermined algorithm. 
 
The neutropenia risk-assessment tool was developed based on these risk 
factors and neutropenia management guidelines published by the American Society 
of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network 
(NCCN). Using the identified variables, a single-page risk-assessment tool was 
developed. They concluded that Use of this risk-assessment tool can help nursing 
staff and practitioners determine which patients are at high risk for chemotherapy-
induced neutropenia. Proactive growth factor support in patients at high risk for 
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chemotherapy-induced neutropenia may be beneficial in decreasing life-threatening 
infections and hospitalizations and in helping deliver effective chemotherapy on time 
and at a planned dose.  
Some studies have done for to know whether prophylaxis with antibiotics will 
reduce the risk of mortality in febrile neutropenia, like in study from M. Paul & A. 
Gafter-Gvili & A. Fraser55 did meta analysis to evaluate whether antibiotic 
prophylaxis in neutropenic patients reduces mortality and incidence of infection and 
to assess related adverse events. Evaluated Ninety-five trials performed between 
1973 and 2004 met inclusion criteria. Fifty-two trials addressed quinolone 
prophylaxis. Antibiotic prophylaxis significantly decreased the risk for death when 
compared with placebo or no treatment (relative risk, 0.67 [95% CI, 0.55 to 0.81]). All 
prophylactic antibiotics were associated with an increased risk for adverse events 
(relative risk, 1.69 [CI, 1.14 to 2.50]). Fluoroquinolone prophylaxis reduced the risk 
for all-cause mortality (relative risk, 0.52 [CI, 0.35 to 0.77]), as well as infection-
related mortality, fever, clinically documented infections, and microbiologically 
documented infections. Fluoroquinolone prophylaxis increased the risk for harboring 
bacilli resistant to the specific drug after treatment and adverse events, but these 
results were not statistically significant (relative risks, 1.69 [CI, 0.73 to 3.92]) and 
1.30 [CI, 0.61 to 2.76], respectively). Concluded that antibiotic prophylaxis for 
neutropenic patients undergoing cytotoxic therapy reduces mortality. Mortality was 
substantially reduced when analysis was limited to fluoroquinolones. Antibiotic 
prophylaxis, preferably with a fluoroquinolone, should be considered for neutropenic 
patients. 
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Whether early lymphopenia after cytotoxic therapy predicts development of 
complications was also seen in some of the studies. 
 
Chul Won Choi, Hwa Jung Sung et al 12 in their prospective study, they 
intended to validate the feasibility of the day-5 lymphocyte count as a predictive 
factor for febrile neutropenia (FN) and define the characteristics of febrile 
neutropenia for their patients. In the results, they also confirmed that early 
lymphopenia was an independent risk factor for FN, and they also defined the 
incidence of FN (18%). Interpretations were proposed for these results.  
 
An early lymphopenia could be a marker of the sensitivity of a patient to the 
hematologic toxicity of chemotherapeutic agents because chemotherapy induces 
lymphopenia before it induces neutropenia. Another possible interpretation was that 
lymphocytes may play a role in the restoration of normal hematopoiesis after 
cytotoxic chemotherapy. The decrease of lymphocyte counts result in a reduced 
production of cytokines, so this could interfere with the restoration of normal 
neutrophil counts. Early lymphocyte recovery was also associated with survival 
advantages in patients with multiple myeloma and non-Hodgkin’s disease who have 
undergone autologous hematopoietic stem cell transplantation.  Therefore, they 
proposed that early immune reconstitution may have a protective effect against 
residual disease progression. 
 
Corticosteroid treatment is a well-recognized cause of lymphopenia ; 
however, all patients received dexamethasone or prednisone as part of 
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chemotherapy or as prevention of emesis or hypersensitivity. Therefore, it is unlikely 
that corticosteroid treatment has a major role in the correlation between lymphopenia 
and FN in their study. 
 
JY Blay, F Chauvin, A Le Cesne42 showed that Early lymphopenia after 
cytotoxic chemotherapy as a risk factor for febrile neutropenia in their study 
Univariate and multivariate analyses of risk factors for FN were performed on a 
retrospective cohort of 112 consecutive patients treated with various chemotherapy 
regimens. Two independent risk factors were identified by the logistic regression and 
used to create a risk model for FN. The validity of the model was tested in three 
distinct groups of patients: two prospective groups of patients treated in two 
institutions (Centre Leon Berard [CLB] and Institut G. Roussy [IGR]) and the group of 
patients with intermediate- or high-grade non- Hodgkin's lymphoma (NHL) treated 
with the doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone 
(ACVBP) regimen between 1988 and 1992 at their centre. Results were, Within the 
retrospective group, 23 of 47 (49%) patients with lymphocyte counts < or = 
700/microL at day 5 after chemotherapy experienced FN compared with seven of 65 
(11%) of other patients (P = .00002). The type of chemotherapy (high dose v others) 
was also significantly correlated to FN (48% v 11%, P = .0003). Age, performance 
status, the number of previous chemotherapy cycles, or polymorphonuclear 
leukocyte (PMN) counts, were not significantly correlated to the incidence of FN in 
univariate analyses. Two independent risk factors were identified in the logistic 
regression: day 5 lymphocyte counts (beta = 1.97 +/- 0.53) and the type of 
chemotherapy regimen (beta = 1.91 +/- 0.53). The calculated probability to 
experience FN in patients with none, one, and both of these risk factors was 4.3%, 
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24.0%, and 68.8%, respectively. The validity of this model was tested in the three 
groups of patients used as validation samples. The observed incidences of FN in the 
above defined risk subgroups were 3%, 19%, and 67%, respectively, within the CLB 
prospective series and 6%, 19%, and 75% within the IGR prospective series. In the 
ACVBP group, the incidence of FN was 33% and 72%, respectively, in patients from 
the intermediate- and high-risk groups. In the two prospective groups and in the 
ACVBP series, the observed numbers of FN in the different risk groups did not differ 
significantly from those calculated by the model (P = .89, P = .86, and P = .72 for 
these three groups, respectively. The conclusions in their study were Day 5 
lymphocyte counts < or = 700/microL and the type of chemotherapy regimen enable 
oncologists to define subgroups of patients treated with chemotherapy as those with 
a high intermediate, and low risk of FN. These criteria could be used to select 
subjects in whom prophylactic measures for FN, in particular hematopoietic growth 
factors, should be proposed. 
 
Malik A, Abbas Z, Karim M 44 did study of Randomised comparison of oral 
ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile 
patients and in their study they compared ofloxacin as an oral single agent with 
standard parenteral combination antibiotics for the management of neutropenic 
febrile patients in a prospective, randomised trial. Patients with severe neutropenia 
(absolute neutrophil count ≤0·5 × 109/l), fever above 38°C, and ability to take drugs 
by mouth were eligible for the study. After initial investigations, 60 patients were 
randomly assigned to oral ofloxacin 400 mg twice daily and 62 to parenteral 
combination antibiotic therapy (amikacin 15 mg/kg daily, plus, at various times in the 
trial, carbenicillin, cloxacillin, or piperacillin).  
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Patients were examined 72 h and 7 days after the start of treatment and when 
neutropenia resolved. 24 (40%) ofloxacin-treated and 26 (42%) combination-treated 
patients had pyrexia of unknown origin (PUO). In both treatment groups, the 
treatment success rate was higher for such patients than for those with clinically or 
microbiologically documented infections (92% vs 67% [p<0·05] for ofloxacin; 85% vs 
64% for combination). There were no significant differences in success rates of 
ofloxacin and combination treatment for these subgroups or overall (77% vs 73%).  
 
Patients with neutropenia for less than 1 week had better responses to both 
treatments than patients with longer-lasting neutropenia. There were 4 (7%) deaths 
in the ofloxacin group and 6 (10%) in the combination group. Both regimens were 
well tolerated. They conclude that oral single-agent ofloxacin is as effective as 
parenteral combination antibiotic therapy in neutropenic febrile patients, especially 
those expected to have short durations of neutropenia 
 
M. Moreau1, J. Klastersky et al 13 did study and, in this study considered all 
haematological tumours and found a 35.4% of incidence of FN per chemotherapy 
cycle. The median neutrophil count at nadir (median 12th day) was 56/µl (range 0–
8750). In the model, eight factors and an interaction were selected for inclusion: 
chemotherapy score, underlying disease, baseline monocyte count <150/µl, body 
surface ≤ 2 m2, use of prophylactic antimicrobial agents, use of prophylactic 
CSF,bone marrow involvement, stem-cell transplantation and the interaction 
between the first cycle of a treatment line and the baseline hemoglobinemia. 
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Although chemotherapy is the most important determinant of the risk of 
neutropenia, they found that no study except the one published by their group 
attempted to develop a general scoring system to compare the aggressiveness of 
the different chemotherapy regimens. Up to now, the aggressiveness of 
chemotherapy has been studied either in terms of delivered dose intensity or of 
presence or not of a particularly aggressive drug in the regimen or as a simple 
comparison of different regimens, making difficult the comparisons between different 
studies. In their study, they used the same methodology as Lalami to score 
chemotherapy regimens according to their myelotoxicity with the objective to develop 
an easy and practical score, assessable before the start of the treatment. 
 
Although the actual dose was not considered for other agents, they indirectly 
included it in the scoring system by taking the average toxicity score of the drugs 
included in the regimen. Although this agent’s classification is not the result of a 
consensus, this methodology has the merit to be a widely applicable method of 
classification because it is not specific to particular chemotherapy regimens. In their 
study, the chemotherapy’s score is one of the most important factors in the 
development of FN. Moreover, that score explained >30% of the variance of FN and 
was the highest among the nine factors of the model. The second most important 
factor in the model was the underlying disease; patients with AML or CML tumor 
have a risk to develop FN and almost nine times higher, respectively, than the 
myeloma. They did not find any other study reporting this finding, probably because 
most of them exclude tumors which could by themselves induce neutropenia, such 
as AML. The role of monocytopenia (measured on days 6–8) in the development of 
CIN has been already reported ; interestingly, their model showed  that even a 
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baseline monocyte count <150/ll is an independent predictor of FN. An early anemia  
and  in general an early drop of all hematopoietic cell counts after the chemotherapy 
has been reported in other studies as potential independent predictors of FN. They 
found the baseline haemoglobin level to be also predictor of FN as an interaction 
with number of cycle. Hemoglobinemia has probably no direct influence on FN, but 
might be reflecting only bone marrow depletion. As it is described in other studies, 
the first cycle of a new treatment is strongly associated with FN in our model. In  their 
study, the variable was included as an interaction with haemoglobin levels in a 
general model that was already valid during the first cycle with an adjustment taking 
into account this characteristic Although older age is usually associated with a higher 
risk of FN in the literature , they found an opposite relation in their study in univariate 
analysis. Some other studies found the same relation in haematological and solid 
tumours. In their sample, this difference between younger and older age can only be 
explained by the higher proportion of stem-cell transplantation among younger 
patients. Anyway, age was not selected by the forward procedure in the final model. 
As found generally in the literature, body surface and bone marrow involvement are 
associated with FN and were selected in the final model. Although the administration 
of prophylactic antimicrobial agents is expected to reduce the occurrence of FN, they 
found an opposite result. It can be easily explained by the fact that the patients are 
not given these drugs randomly, but only when the risk of neutropenia is higher or on 
the basis of the medical indication. As some studies found that baseline and early 
lymphopenia (on day 5) might be associated with FN. They did not find an 
association between a low baseline lymphocyte count and FN, neither in univariate 
nor in multivariate analysis. In the development of this prediction rule, they did not 
include prophylactic antimicrobial agents administration and prophylactic CSF 
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administration, considering them as simple adjustment variables. They conclude that 
a score of15 (first cycles) and 10 (further cycles) gives the best results in term of 
sensitivity, specificity and predictive value and could be used as cut-offs to 
administer CSF, which would increase a little its use (absolute increase of 2% 
expected AML). 
 
S Kelly and D Wheatle et al 14 said that there is good evidence to suggest that 
dose intensity is important when considering the effectiveness of adjuvant 
chemotherapy in patients with breast cancer. However, the development of 
chemotherapy-induced febrile neutropenia can lead to reduction in dose intensity 
and other treatment modifications, which may negatively affect patient outcomes. 
Febrile neutropenia can be prevented by the use of primary prophylactic treatment, 
notably with granulocyte colony-stimulating factors. This practice is supported by 
international guidelines, all of which recommend that primary prophylaxis with 
granulocyte colony-stimulating factors should be used with chemotherapy where the 
risk of febrile neutropenia is 20% or greater. 
 
Essentially, two approaches are available for selecting a population of 
patients at low-risk. The first one is to rely on a set of predictive factors published in 
the literature or chosen on the basis of clinical expertise without analyzing the 
interaction between them but rather combining them empirically. The advantage of 
this approach is that the definition of low-risk may be changed very easily depending 
on the context of use and on the occurrence of new studies’ results. The 
disadvantage is that it is very difficult to assess the performance of the definition in 
terms of sensitivity, specificity and positive and negative predictive values. The 
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following factors are often considered to delineate low-risk: absence of 
hemodynamic instability, absence of hypotension, no altered mental status, no 
respiratory failure, no renal failure, no abnormal hepatic tests, good clinical condition, 
an expected short duration of neutropenia, no acute leukaemia, no bone marrow or 
peripheral blood stem cell transplant, absence of chills, no abnormal chest X-ray, no 
cellulitis or signs of focal infection, no catheter-related infection, no need for 
intravenous supportive therapy 16.  
 
This was the most frequently adopted methodology for the clinical trials which 
tested oral antibiotic regimens as an alternative for patients considered at low-risk. 
The second, more recent approach is to try to develop validated models integrating 
several factors in a well-defined way and considering their independent value or their 
interactions. Models have first to be developed and then tested on a separate 
patients population in order to be certain that they are well calibrated (predicted 
outcomes have to match observed outcomes) and reliably transportable in other 
settings (to other institutions for instance); alternatively, cross-validation techniques 
may be used. Their discrimination ability also has to be regularly monitored. 
Advantages are that such an assessment of low-risk is standardized and more 
objective and that the classification has known properties. The method is also more 
parsimonious with the use of independent only predictive factors. The predicted 
outcome is also more carefully defined. However, the development process is long; 
the need for validation should not be underestimated and the context of use has to 
be considered before introducing thin clinical practice. 
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As of now, for populations of adult patients, two popular scoring systems have 
been developed and validated: the Talcott model and the MASCC score. Both use 
the same endpoint: the occurrence of serious medical complications (and not the 
response to empiric treatment). The choice of this endpoint was stressed as a 
progress in the discussion of risk assessment, although the definition of a serious 
medical complication may appear somehow arbitrary. Indeed, the need to change 
empiric treatment does not necessarily mean that the clinical course of the patient 
will not be benign and is felt as less adequate in estimating the risk associated to 
groups of patients16. 
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STUDY DESIGN 
This single centre prospective and observational study was performed at 
department of medical oncology of cancer institute, Chennai .Total of 100 
consecutive febrile neutropenia episodes studied from August 2010 to March 
2011.Patient data was collected in separately designed proforma for the study. 
PATIENT SELECTION 
All consecutive febrile episodes occurring in patients meeting the following 
eligibility criteria were included: histologic diagnosis of malignancy, neutropenic 
febrile secondary to chemotherapy and/or radiotherapy, fever and age more than 18 
years. 
Neutropenia was defined as  absolute neutrophil count (ANC) less than 
500/µl, including polymorphonuclear leukocytes and band forms or ANC less than 
1000/ µl expected to fall below 500/µl , within 24 hours. Fever was axillary 
temperature ≥38o C documented by the patient or the medical /nursing staff. 
TREATMENT AND RISK ASSESSMENT 
All patients underwent a detailed history taking and complete physical 
examination and were assessed by MASCC score in first 24 hours of study 
admission.  
 
 
 
33 
 
MASCC RISK SCORE 
CHARACTERISTIC RISK SCORE 
Burden of illness 
No or Mild symptoms 
Moderate symptoms 
 
03 
05 
No Hypotension 05 
No chronic obstructive pulmonary 
disease 
 
04 
Solid tumour or no previous fungal 
infection in hematologic tumour 
 
04 
Outpatient status 03 
No dehydration 03 
Aged <60 years 02 
 
Patients with a score ≥21 were considered to be at low risk and less than that 
were considered to be at high risk. 
All included patients were followed daily until discharge from hospital and 
those individuals that left the hospital kept as day care and received oral antibiotics 
were also followed. 
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Antibiotics were maintained until the ANC recovered to over 500/µl, and the 
patient had remained afebrile for 48 hours. Patient’s clinical examination presence of 
mucositis, dehydration and any system involvement were documented.  
DEFINING SERIOUS MEDICAL COMPLICATIONS  
Serious medical complications were considered if the patient developed at least one 
of the following pre defined categories:  
1. Antibiotic treatment change secondary to recurrence or persistent fever 
(unexplained fever higher than 38o C for ≥5 days, or fever higher than 39oC 
persisting after 72 hours of antibiotic therapy), development of a new 
clinical localisation of infection, clinical deterioration, serious adverse 
effects related to antibiotics, or bacterial sensitivity profile. 
2. Clinical deterioration secondary to febrile neutropenic episode predefined 
as fallowing: presence of arterial hypotension (systolic blood pressure <90 
mm Hg or need for medicine support to maintain blood pressure); 
respiratory failure (respiratory rate 24 breaths /min, arterial oxygen 
pressure less than 60 mm Hg while breathing room air ,or need for 
supplemental oxygen); confusion or altered mental status leading to 
diagnostic work up; renal failure (requiring investigation and/or treatment 
with parenteral fluids, dialysis ,or any other intervention; severe 
gastrointestinal disorder ;or sepsis. 
3. Hospital readmission relate to neutropenic episode. 
4. Dehydration requiring prolonged parenteral fluids replacement (>3 days). 
5. Haemorrhage resulting in blood transfusion. 
6. Platelet count <20,000/µl. 
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7. ECG changes and arrhythmias requiring urgent therapy. 
8. Persistence of positive blood cultures or breakthrough bacteremia. 
9. Intensive care unit admissions. 
10. Death. 
11. Other abnormalities judged serious and clinically significant by the 
investigator. 
STATISTICAL ANALYSIS.  
Descriptive statistics were used to express patient characteristics as 
frequencies. For calculation of sensitivity and specificity, a 2X2 table was used. The 
positive predictive value (PPV) was calculated for low risk patients predicted to have 
an uncomplicated recovery, and the negative predictive value (NPV) were calculated 
for high-risk patients who were predicted to indeed develop serious medical 
complications. Chi square test was used to identify significance individual 
parameters.  
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The  total number of  febrile neutropenia episodes studied was 100. Fallowing 
were the results observed.  
 
Table 1 :   Distribution of cases according to sex. 
 
SEX  DISTRIBUTION  (100 PATIENTS) 
 
MALE  46 
 
FEMALE  54 
 
Figure 1:   Distribution of cases according to sex. 
 
 
 
 
 
38 
 
Table 2:   Age of the patients 
 
 
AGE  OF PATIENTS    ( MEDIAN AGE 39.5 YEARS) 
 
 
≤ 50 YEARS 
 
75 
 
 
> 50 YEARS 
 
25 
 
 
Figure 2:   Distribution of patients according to type of cancer. 
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Table 3:   Total count and number of patients. 
 
TOTAL  COUNT 
 
NO OF PATIENTS 
 
≤ 500  14 
 
501 – 1000  34 
 
1001‐ 1500  38 
 
MORE THAN 1501  14 
 
 
Figure 4:   Total count and number of patients. 
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Table 4 :   Distribution of patients according to absolute neutrophil 
count (ANC). 
 
ABSOLUTE NEUTROPHIL 
COUNT 
NO OF PATIENTS 
 
 
≤ 100  13 
 
101 ‐ 500  83 
 
501 AND ABOVE  04 
  
 
Figure 4 :   Distribution of patients according to absolute neutrophil 
count (ANC). 
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Table 5:   System involved during episode of febrile neutropenia 
(clinical). 
 
SYSTEM INVOLVED (CLINICALLY)  NO OF PATIENTS 
 
RESPIRATORY SYSTEM  44 
 
GASTROINTESTINAL  TRACT  15 
 
ORAL CAVITY  01 
 
URINARY TRACT  01 
 
MULTI SYSTEM  05 
 
NO IDENTIFIABLE FOCUS  34 
 
Figure 5:   System involved during episode of febrile neutropenia 
(clinical). 
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Table 6:   Number of patients with major complications. 
 
MAJOR COMLICATIONS  NO OF PATIENTS 
 
YES  32 
 
NO  68 
 
 
 
Figure 6:   No of patients with major complications. 
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Among one hundred episodes thirty two were associated with major 
complications and sixty eight were not associated with any major complications. 
Total of thirty five episodes were categorised as low risk, of those only one patient 
developed major complication and sixty five were categorised as high risk and thirty 
one of them developed major complication.   
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Table 7 :   Number of patients who received G‐CSF. 
 
 
G‐ CSF GIVEN  NO OF PATIENTS 
 
YES  77 
 
NO  23 
 
Table 8:   Sensitivity and Specificity of MASCC Risk Score. 
   
 
 
MASCC risk score had sensitivity of 50% and specificity of 96%. It also 
showed positive predictive value (PPV) and negative predictive value (NPV) of 
97.7% and 47.7% respectively. 
 
 
 
MASCC RISK 
SCORE 
NO OF 
PATIENTS 
NO OF PATIENTS 
WHO HAD MAJOR 
COMPLICATION 
SENSITIVITY  SPECIFICITY
 
≥ 21 
 
35  01   
50% 
 
 
96% 
 
< 21 
 
65  31 
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Table 9:   ANC and Major Complications 
Absolute 
neutrophil 
count(ANC) 
Total no of 
patients 
No of patients 
who had 
major 
complications
Percentage of 
patients who 
had major 
complications 
 
P value 
 
< 100 
 
13  10 
 
76.9% 
 
 
 
0.001  
101 ‐ 500 
 
83  21  25.3% 
 
> 500 
 
04  01  33.0% 
 
 
 
Patients who had low ANC were prone for more major complications than 
patients who had better ANC count. This was statistically significant (0.001). 
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Table 10 :  Performance status (PS) and Major Complications 
 
 
PS 
Total no of 
patients 
No of patients 
who had 
major 
complications
Percentage of 
patients who 
had major 
complications 
 
P value 
 
1 
 
15  01 
 
6.7% 
 
 
 
 
 
0.0001 
 
2 
 
 
70  18  25.7% 
 
3 
 
 
14  12  85.7% 
 
4 
 
01  01  100% 
 
 
Patients who had poor PS at presentation were more prone to develop major 
complications subsequently, which was statistically significant (0.0001). 
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Table 11:   Major Complications and No of patients. 
 
MAJOR COMPLICATION 
 
NO OF PATIENTS (32) 
Bleeding severe enough to require blood 
transfusion 
07 
Platelet count less than 20000 05 
Hypotension and sepsis 06 
Patients requiring ICU admission 05 
Respiratory failure and Hypotension 02 
ECG changes and arrhythmias requiring 
urgent therapy 
02 
Platelet count less than 20000 and 
Patients requiring ICU admission 
05 
 
 
Total 32 among 100 episodes were associated with major complication, 
Bleeding severe enough to require transfusion was the Commonest Complication 
seen (07 patients), followed by hypotension and sepsis (06 patients). Platelet count 
less than 20,000, ICU admission was seen in 5 patients each. 5 patients had both 
platelet less than 20,000 and ICU admission. There were no any deaths. 
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Table 12:   Culture Positivity and System involved. 
 
System involved 
Total no culture 
Positivity 
 
Organisms isolated 
 
Respiratory system 
(Sputum) 
07 
4 – Klebsiella 
1 – Candida 
1 – Candida & S.Aureus 
1‐ Klebsiella & S.Aureus 
 
Blood  02 
1 – Klebsiella 
1‐  S.Aureus 
 
Urinary tract 
(Urine) 
 
02 
1‐ MDR Enterococcus
1‐ S.Aureus 
 
 
There were 10 patients who had culture positivity as shown in Table 12 . 
Klebsiella was the commonest organism isolated from culture. 
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Discussion 
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In our study which had total of one hundred episodes of febrile neutropenia 
.Thirty was solid malignancy cases and seventy haematological. Total of thirty two 
patients had major complications. MASCC risk score had sensitivity of 50%, 
specificity of 96%, Positive predictive value and Negative predictive value were 
97.7% and 47.7% respectively. Low Absolute neutrophil count and Poor 
Performance status were significant risk factors in our study. Respiratory system was 
the common system involved clinically in our study.  Eleven patients had culture 
positivity, seven from respiratory system, two each from blood and urinary tract. 
Klebsiella was the commonest organism which was isolated. 
 
The development of validated risk assessment tools will facilitate the 
identification of a group of low risk patients with febrile neutropenia at the onset of 
fever and the selection of newer therapeutic approaches including oral and/or 
outpatient therapeutic strategies for the “low risk” group.  
 
Various studies using MASCC risk score index have reported various 
sensitivity, specificity, positive predictive value and negative predictive value.2, 17, 18  
In study done at our centre as mentioned earlier we had one hundred 
episodes of febrile neutropenia which had 54 female and 46 male patients.  70% of 
were haematological malignancies and 30% were of solid malignancies. Total of 77 
patients received growth factors. 
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Among hundred patients in our study, 32 patients developed major 
complications. Thirty five patients had MASCC risk score of 21 or more and 
classified as low risk among which only one patient had major complication (1/35). 
Total of sixty five patients had MASCC risk score of less than 21 and thirty one of 
them had major complications (31/65). 
 
Jean Klastersky et3 al validated this score in756 patients, Multinational 
Association for Supportive Care in Cancer risk-index score > 21 identified low-risk 
patients with a positive predictive value of 91%, specificity of 68%, and sensitivity of 
71%.Concluded that the risk index accurately identifies patients at low risk for 
complications and may be used to select patients for testing therapeutic strategies 
that may be more convenient or cost-effective3.  
 
Edwin Pun Hui & Linda K. S. Leung et al5 studied 227consecutive patients.  
They compared MASCC risk score with Talcott model. Serious medical 
complications occurred in 22% of patients and 4% died. The positive predictive value 
of low risk prediction was 86% (95% CI=81–90%) for MASCC score≥21, sensitivity, 
specificity, negative predictive value were 81%,60% and 52%, respectively, for 
MASCC score≥21. They concluded that the MASCC risk index is prospectively 
validated in a Chinese population. It demonstrates a better overall performance than 
the Talcott model 
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In study reported from Inner H et al18, where they studied total of 100 febrile 
neutropenia episodes occurring in 83 patients which included malignancies of solid 
tumours and lymphomas. They had around 90% of them being in low risk, of which 
75 were treated with oral antibiotics. They had a positive predictive value of 96.7%% 
for MASCC index for identifying low risk patients. 
 
They concluded that the MASCC risk index is both feasible and safe when 
used in standard clinical practice to guide the management of febrile neutropenia in 
patients with solid tumours and lymphomas. They also felt that patients predicted to 
have low risk can be managed safely with oral antibiotics and early hospital 
discharge. 
 
Our study showed sensitivity of 50% and specificity of 96%, positive predictive 
value and negative predictive value of 97.7% and 47.7% respectively. There by 
among the patients who had low risk based on MASCC risk score only one patient 
had major complication (1/35). However the study had low negative predictive value 
as among sixty five patients who were categorised as high risk, only thirty one of 
them developed major complication. 
 
B.L. repoport et al19 from south Africa published their results in ASCO 2003, 
they collected data from 80 febrile neutropenic episodes prospectively (19 males and 
61 females). Fifty six patients had solid tumours and twenty four haematological 
malignancies. Among which 22 patients were classified as high risk and only 10 
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developed complications. 58 patients who were categorised as low risk and 1 patient 
developed major complication. This study had 95% of positive predictive value in 
identifying low risk patient. Like in our study it had low negative predictive value as 
among 22 classified as high risk only 10 developed major complications. 
 
Below is the table which compares different studies with our study. As we can 
see that almost al studies had high Positive Predictive Value (PPV) in identifying low 
risk patients.  
 Sensitivity  Specificity PPV NPV 
Our Study 50% 96% 97.7% 47.7% 
Edwin et al5  81% 60% 86% 52% 
Repport et al19   95%  
Inner H et al18   96.7%  
J Klastersky et al 3 71% 68% 91%  
 
However some studies have failed to show impact of MASCC risk score in 
stratifying low risk patients.  
 
J. Bajpai et al20, in their study had total of 178 febrile neutropenia episodes 
(22 in solid tumors and 16 in hemato lymphoid malignancies).They concluded that 
the association between MASCC score and risk stratification could not be 
established. 
54 
 
Various studies have reported different rate and organisation in their culture 
positivity at their respective centre. In our study we had total of 11 (11) culture 
positivity among 100 episodes. Majority were sputum (7) culture sensitivity. 
Klebsiella was the commonest organism isolated. 
 
In study from J. Bajpai et al had 59 episodes of culture positivity out of 178 
episodes and E coli as the commonest organism that was isolated.  
 
De Souza  vienna et al in their study of 60 episodes of febrile neutropenia had 14 
patients (26%), who had micro biologically documented infection, and gram negative 
pathogen was the main etiologic agent. Respiratory tract was the most common 
source as in our study.  
 
In their study oral cavity and oropharynx was most common site of clinically 
documented infection. In our study Respiratory system was most common site of 
clinically documented infection (Table no. 5) 
 
Different factors and parameters along with MASCC risk score were also 
associated with development of major complications. 
 
In study from Escalante et al observed that patients with mucositis >grade 2 
were associated with more possibility of developing major complications. 
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Though study from J Bajpai et al failed to show any impact of MASCC risk 
score, they found that mucositis, maximum temperature > 103 F, age high dose 
steroid were associated with major complications. 
 
In our study the poor performance status and low absolute neutrophil count 
(ANC) were associated with major complications (p value of 0.0001 and 0.001 
respectively), patients who had poor PS and low ANC were more likely to have more 
chance of developing major complications. There by patients with ANC less than 100 
and PS 3 or 4 may need treatment as in patients. 
 
Our study showed high positive predictive value for low risk patients. Patients 
with MASCC risk score of >21 are unlikely to develop major complications and they 
can be managed as day care patients. 
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Conclusion 
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• MASCC risk score had high specificity, positive predictive value and low 
sensitivity, negative predictive value for identification of low risk patients in 
our study. 
• 11% of patients had microbiologically documented injection and Klebsiella 
was the commonest organism which was isolated  
• Respiratory system was most common system involved clinically  
• Poor performance status and low absolute neutrophil count were 
associated with major complications which was statistically significant 
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PROFORMA 
 
NAME ‐ _______________________AGE ‐ _______yrs ,_____SEX ‐ M/F 
 
OP NO‐________________________PS‐ ____ 
 
 
TYPE OF CANCR – SOLID/HEMATO_______ANTIBIOTIC PROPHYLAXIS – YES/NO 
 
PREVIOUS  FEBRILE  NEUTROPENIA – YES/NO   TEMP ‐  
 
DEHYDRATION – YES/NO                   ORAL MUCOSITIES – YES / N 
____________________________Grade    
            
 
 
Total Count ‐  
Less than 
500 
500 to 
1000  
1001 to 1500  1501 to 2000  2001 and 
more 
     
             
 
     
0  1 2 3  4
 
0  1 2 3  4
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ANC Count ‐  
                       
MASCC Index score 
Characteristic     
Burden of illness 
*No or mild symptoms  
*Moderate symptoms  
 
5 
3 
 
No hypotension   5   
No chronic obstructive 
Pulmonary disease  
4   
Solid tumor or no previous 
fungal infection 
4   
Outpatient status  
No dehydration  
3 
3 
 
Aged <60 years   2   
TOTAL     
Clinically documented infection       Yes/No 
Respiratory tract   
Gastrointestinal tract
Oral cavity and oropharynx   
CNS   
Sepsis   
Fever of unknown origin   
   
 
Less than 100 101 to 500 501 to 1000
66 
 
Microbiologically documented infection  ‐     Yes/No   
 
Bactremia without identifiable focus 
Catheter Related 
Urinary tract 
Respiratory tract 
Gastrointestinal tract 
Soft tissue infection 
Any other source  
Antibiotics given – Yes/No  , If yes ‐   Oral/ IV    
Name and Duration                                       Days ‐        
Growth factor  Yes /No    Days ‐
 
 
 
 
 
 
Bacterial 
Fungal 
Viral 
Others 
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Major complications – Yes/No ,If yes then which of fallowing  
 Fever Duration 
Hypotension , Respiratory failure renal 
failure, severe GIT disorders or sepsis. 
Intensive care unit admission 
Dehydration requiring  prolonged 
Parenteral fluids ( 3 days)  
Confusion or altered mental state. 
Persistence of positive blood culture or 
breakthrough bacteremia. 
Bleeding severe enough to require 
transfusion 
ECG changes and arrhythmias requiring 
urgent therapy. 
Platelet count less than 20000. 
Death  
Other complications  
 
 
 
 
